Life sciences analytical technology firm SCIEX has completed the acquisition of Silicon Valley-based Intabio.
SCIEX acquired the biotherapeutic analysis and quality assessment firm for an undisclosed amount. According to a release from SCIEX, Intabio’s Blaze System coupled with high-resolution mass spectrometry can reduce sample prep and increase throughput.
“With our combined knowledge of the biopharma market, capillary electrophoresis and mass spectrometry, we believe we can significantly simplify how our customers bring life-saving drugs to market faster,” Inese Lowenstein, president at SCIEX, said in the release.
Intabio associates and products will transition into SCIEX while continuing to operate from its existing facilities in Fremont, Calif., according to the release.
